Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.78 |
| ▸ | RAB9A | P51151 | 3/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.78 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.68 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276277 | 1.00 | MAPT (0.78) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL30184671 | 0.89 | RAB9A (0.72) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL591905 | 0.89 | RAB9A (0.72) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL155002 | 0.88 | MAPT (1.00) | MAPTRAB9ANPC1LOXL2TP53 | |
| Benzene SCHEMBL28280876 | 0.87 | RAB9A (0.70) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL439174 | 0.87 | MAPT (0.70) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL11623669 | 0.86 | MAPT (0.68) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL2567453 | 0.86 | MAPT (0.68) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL14402606 | 0.86 | MAPT (0.68) | MAPTRAB9ANPC1LOXL2ELANE | |
| SCHEMBL7793708 | 0.86 | MAPT (0.68) | MAPTRAB9ANPC1LOXL2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336868-A1 | COMPOSITIONS COMPRISING ADAMANTYL ESTER-CONTAINING COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2024-10-10 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| WO-2023230543-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230012655-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UNIV TUFTS (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3693372-A1 | BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2020-08-12 | — | — | EP | disclosed |
| EP-2970158-B1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | BIOELECTRON TECH CORP (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2968303-B1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | UNIV COLUMBIA (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2627178-B1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-3000808-B1 | 5-((HALOPHENYL)-3-HYDROXY-PYRIDIN-2-YL)-CARBOXYLIC ACID DERIVATIVES AS INTERMEDIATES FOR THE PREPARATION OF CARBONYLAMINO ALKANOIC ACIDS, ESTERS AND AMIDES THEREOF | AKEBIA THERAPEUTICS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-8901152-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-4074046-A | REACTING NITROGENEOUS COMPOUND WITH CARBON MONOXIDE | AMERICAN CYANAMID COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | MAPT 1301/4885RAB9A 1581/4885NPC1 243/4885 |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | MAPT 2094/4885RAB9A 1874/4885NPC1 180/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | MAPT 3027/4885RAB9A 1504/4885NPC1 2010/4885 |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | MAPT 4003/4885RAB9A 1707/4885NPC1 706/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | MAPT 3400/4885RAB9A 627/4885NPC1 527/4885 |
| US-20230012655-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UMPS, UPP1, UGDH | MAPT 56/4885RAB9A 246/4885NPC1 1110/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | MAPT 4379/4885RAB9A 2066/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.